INVICTUS HIRES INTERIM CHIEF MARKETING OFFICER AND EXPANDS INVESTOR RELATIONS

Date : 02/13/2019 @ 2:32PM
Source :InvestorsHub NewsWire
Stock : Invictus MD Strategies Corp (GENE)
Quote : 0.34  -0.005 (-1.45%) @ 3:02PM

INVICTUS HIRES INTERIM CHIEF MARKETING OFFICER AND EXPANDS INVESTOR RELATIONS


 

Vancouver, BC -- February 13, 2019 -- InvestorsHub NewsWire -- INVICTUS MD STRATEGIES CORP. ("Invictus" or the "Company") (TSXV: GENE; OTCQX: IVITF; FRA: 8IS1) is pleased to announce that it has hired a prominent Toronto based strategic consulting agency (the “Agency”) as interim Chief Marketing Officer (“interim CMO”), strategic consulting partner, creative agency partner and live events partner. The contract duration is six months and began on January 1, 2019.

With over 35 years of branding experience in the healthcare sector, the Agency will leverage its expertise to help create, develop, and execute the go-to-market strategy for Invictus cannabis products. As interim CMO, the Agency will work with Authentic Brands Group (“ABG”) and Invictus’ senior leadership team to facilitate the anticipated launch of Invictus’ medical brand T2C, and adult recreational brands under Dukes and Sterling & Hunt.

Invictus will compensate the Agency with a monthly fee of $45,000 CAD, payable in common shares of Invictus using a per share issue price equal to the greater of: (i) the 30-day volume weighted average price (“VWAP”) of the Company’s common shares on the TSX Venture Exchange for December 2018 (adjusted for any share consolidation of the Company); and (ii) the maximum discount allowable under the TSX Venture Exchange policies on the date of issuance.

To bolster the Company’s profile, Invictus has enlisted Darwin Productions Inc. (“Darwin”) to provide investor relations and marketing services. The Company’s contract with Darwin is for $25,000 CAD per month. In addition, Darwin will provide a direct mail scheduled for distribution in early March. This campaign will cost approximately $500,000 USD and reach nearly 500,000 households in North America, providing company information to build brand awareness.

The Company has also granted 250,000 stock options to a certain advisor of the Company. Each stock option has an exercise price of $1.00 and is exercisable into one common share of the Company. The options vest immediately and are exercisable over a period of five years. The stock options were granted subject to the terms and conditions of the Company's Stock Option Plan.

For more information, please visit www.invictus-md.com.

On Behalf of the Board,
George E. Kveton
Chief Executive Officer and Director

Jessica Martin
Vice President, Public Relations and Regulatory Affairs
(833) 879-4363

About Invictus

Invictus is a global cannabis company offering a selection of products under a wide range of brands. Our integrated sales approach is defined by five pillars of distribution including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores.

Invictus has partnered with business leaders to convey our corporate vision, including KISS music legend and business mogul Gene Simmons as our Chief Evangelist Officer. To meet growing demand, Invictus is expanding its cultivation footprint, with three cannabis production facilities licensed under the Cannabis Act and Cannabis Regulations in Canada. To accommodate international sales, Invictus’ wholly-owned subsidiary, Acreage Pharms Ltd., has designed and is currently building its Phase 3 purpose-built cultivation facility to be European Union Good Manufacturing Practices compliant. The Company is targeting for up to 50 percent of its production to comprise medical cannabis. To ensure consistency in quality and supply, Invictus maintains all aspects of the growing process through its subsidiary, Future Harvest Development Ltd., a high-quality fertilizer and nutrients manufacturer. Invictus drives sustainable long-term shareholder value through a diversified product portfolio with over 70 Health Canada approved strains and a multifaceted distribution strategy including medical, adult-use, international, Licensed Producer to Licensed Producer and retail stores. For more information visit www.invictus-md.com.

Cautionary Note Regarding Forward-Looking Statements: This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws or forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, timing, assumptions or expectations of future performance, including the Company’s launch of Invictus medical and adult recreational brands under T2C, and Dukes and Sterling & Hunt, respectively, is a forward-looking statement and contain forward-looking information. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including that the Company will complete its launch of Invictus medical and adult recreational brands under T2C, and Dukes and Sterling & Hunt, respectively. This forward-looking statement is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, that the Company will not complete its launch of Invictus medical and adult recreational brands under T2C, and Dukes and Sterling & Hunt, respectively. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
 

Invictus MD Strategies (TSXV:GENE)
Historical Stock Chart

1 Year : From Jul 2018 to Jul 2019

Click Here for more Invictus MD Strategies Charts.

Invictus MD Strategies (TSXV:GENE)
Intraday Stock Chart

Today : Tuesday 23 July 2019

Click Here for more Invictus MD Strategies Charts.

Latest TSXV:GENE Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.